Related Experiment Video
Updated: Jul 27, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in
Jay Maradia1, Shirish S Joshi1, Amitoj Sohal1
1Pharmacology and Therapeutics, Seth Gordhandas Sunderdas Medical College and King Edward Memorial (KEM) Hospital, Mumbai, IND.
Abstract:
The editorial discusses the beneficial effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with diabetic nephropathy and their underutilization in government hospitals in India for the treatment of diabetic nephropathy. The authors provide a comprehensive analysis of various factors contributing to the under-prescription of these medications, including lack of awareness and education among healthcare professionals, limited availability and accessibility of medications, high cost, and poor adherence to evidence-based guidelines. Addressing these factors through education, research, and affordable pricing and reimbursement policies may help improve the appropriate prescription of SGLT-2 inhibitors in government hospitals in India.
Related Concept Videos
Secondary Active Transport
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Sulfonylureas

